ライフサイエンスコーパス: galectin 1

1 were measured in the presence and absence of galectin-1.

2 (nanoplexes) to inhibit gene expression for galectin-1.

3 ginex, we had yet to prove that 0118 targets galectin-1.

4 e-host cell interaction via binding to human galectin-1.

5 ender thymocytes susceptible or resistant to galectin-1.

6 for a ubiquitous galactoside-binding lectin galectin-1.

7 as mediators of the DC activation effects of galectin-1.

8 for a ubiquitous galactoside-binding lectin galectin-1.

9 e 2 O-glycan expression or susceptibility to galectin-1.

10 om a patient with MF, were also resistant to galectin-1.

11 that allow recognition and cross-linking by galectin-1.

12 equired for maximal T cell susceptibility to galectin-1.

13 te BCR signaling through an association with galectin-1.

14 n receptors distinct from that recognized by galectin-1.

15 n contrast to the CD45 clustering induced by galectin-1.

16 pressing the beta-galactoside-binding lectin galectin-1.

17 toplasmic levels of the nanocluster scaffold galectin-1.

18 dothelial cells against apoptosis induced by Galectin-1.

19 e-arene interactions for galectin-3 than for galectin-1.

20 -glycans able to establish interactions with Galectin-1.

21 ins, annexin A4, cyclophilin A, cathepsin D, galectin-1, 14-3-3zeta, alpha-enolase, peroxiredoxin I,

22 tein that possesses nine LacNAc epitopes, to galectin-1, -2, -3, -4, -5, and -7, and truncated, monom

23 galectin family of glycan binding proteins (galectins-1, -2, and -4) induce PS exposure in a carbohy

24 Galectin-1, a beta-galactoside-binding lectin, is involv

25 Galectin-1, a beta-galactoside-binding protein highly ex

26 Galectin-1, a member of the conserved family of carbohyd

27 We examined the effects of galectin-1 ablation in the context of class-I-restricted

28 The latter two are specific features of galectin-1-activated DCs.

29 We previously showed that galectin-1 activates human monocyte-derived dendritic ce

30 at complexes containing H-ras conformers and galectin-1 affect both the number and lifetime of nanocl

31 We propose that galectin-1 aids in discriminating TCR-directed fate deci

32 nfirming previous studies, morphine alone or galectin-1 alone enhance HIV-1 infection of MDMs.

33 many of the same DC maturation genes as LPS, galectin-1 also uniquely up-regulated a significant subs

34 CD45 is a glycoprotein receptor for galectin-1, an endogenous lectin that can trigger lympho

35 We demonstrate that galectin-1 and -3 are expressed by the human cervical an

36 ozoan derivatives to dissect the function of galectin-1 and -3 in the context of Trichomonas infectio

37 Inhibitors for galectin-1 and -3 were synthesized from thiodigalactosid

38 The homodimeric adhesion/growth-regulatory galectin-1 and a set of covalently linked homo-oligomers

39 there was a significant correlation between galectin-1 and CA IX staining (P = .01) and a strong inv

40 01) and a strong inverse correlation between galectin-1 and CD3 staining (P = .01).

41 Expression of galectin-1 and CD3 were significant predictors for overa

42 s and revealed concomitant overexpression of galectin-1 and CXCR4 associated adversely with overall a

43 ignificance and positive correlation between galectin-1 and CXCR4 expression levels and revealed conc

44 The coordinated upregulation of galectin-1 and CXCR4 may be a novel prognostic factor fo

45 We have shown that galectin-1 and galectin-3 are functionally redundant spl

46 Previously, we showed that galectin-1 and galectin-3 are redundant pre-mRNA splicin

47 Concomitant incubation with exogenous galectin-1 and morphine potentiated HIV-1 infection of M

48 f 3.10(-7) M, and specific as CD146 binds to Galectin-1 and not to Galectin-2.

49 mmunosuppressive microenvironment, including galectin-1 and PD-L1/2.

50 Additionally, two secreted proteins, galectin-1 and progestagen-associated protein 14, known

51 the specificity of Gal-3BP interacting with galectin-1 and the role of Gal-3BP in cancer cell aggreg

52 ghly up-regulated genes include SOX5, CD11C, galectin-1, and FGR, similar to a previously described F

53 Here, we report the identification of galectin-1, and related galectins, as a novel OCA-B-inte

54 that nanoplexes silenced gene expression for galectin-1, and they reversed the effects of morphine on

55 polypeptide, apolipoproteins A-Ib and A-II, galectin-1, and vitellogenin-6 during degeneration when

56 In a murine lymphedema model, galectin-1(-/-) animals had increased numbers of migrato

57 Furthermore, recombinant galectin-1 antagonized binding of agonist tetramers to t

58 Because both CD146 and Galectin-1 are involved in modulation of cell apoptosis,

59 Our results also support a critical role for galectin-1 as a GM1 cross-linking counter-receptor that

60 This study thus identifies Galectin-1 as a master regulator of clinically relevant

61 Altogether, our results identify Galectin-1 as a novel ligand for CD146 and this interact

62 R of OT-1 thymocytes, these studies identify galectin-1 as a tuner of TCR binding, signaling, and fun

63 general, our data indicate that 0118 targets galectin-1 as an allosteric inhibitor of glycan/carbohyd

64 oscopy demonstrates that 0118 indeed targets galectin-1 at a site away from the lectin's carbohydrate

65 Binding to galectin-1 at the extracellular surface prevents clathri

66 -mediated glycosylation of RPTPbeta promotes galectin-1 binding and RPTPbeta levels of retention on t

67 Moreover, galectin-1 binding clustered CD43 modified with either c

68 ts in decreased RPTP retention, showing that galectin-1 binding contributes to the increased retentio

69 The galectin-1 binding domain in OCA-B has been localized to

70 Glycan-dependent Galectin-1 binding induced a set of disease markers, inc

71 lated, contributes a significant fraction of galectin-1 binding sites on T cells, as T cells lacking

72 pression of core 2 O-glycans did not enhance galectin-1 binding to CD43 on T cells.

73 and the effects of O-glycan modification on galectin-1 binding to CD43.

74 Galectin-1 binding to surface CD43 and CD45 on MDDCs ind

75 The sugar-galectin-1 binding was also examined.

76 Galectin-3 and galectin-1, binding partners of LGALS3BP, potentiate mon

77 studies showed that after klotho treatment, galectin-1 binds the TRPV5 N-glycan and thereby increase

78 Galectin-1 binds to N- and O-glycans on several glycopro

79 Specifically, galectin-9 and galectin-1 both kill thymocytes, peripheral T cells, and

80 in-1-induced cross-linking and T cell death, galectin-1 bound to CD43 fusion proteins modified with e

81 was blocked by intracellular Bcl-2, whereas galectin-1, but not galectin-9, T cell death was blocked

82 Galectin-1, but not lipopolysaccharide, stimulated Syk p

83 xia-induced peak at 15 kDa that proved to be galectin-1 by MS analysis.

84 ed tumor tissues from 101 HNSCC patients for galectin-1, CA IX (carbonic anhydrase IX, a hypoxia mark

85 The interaction of OCA-B and galectin-1 can be detected both in vivo and in vitro.

86 , providing an additional mechanism by which galectin-1 can dampen immune responses.

87 s, in the present study, we demonstrate that galectin-1 can enhance NiV attachment to and infection o

88 Thus, galectin-1 can have dual and opposing effects on NiV inf

89 Interestingly, we also found that galectin-1 can prime DCs to respond more quickly to low

90 Endogenous human lectins, such as galectin-1, can function as pattern recognition receptor

91 s of bivalent constructs with galectin-9 and galectin-1 carbohydrate recognition domains connected by

92 However, as galectin-3 and galectin-1 cell death are neither additive nor synergist

93 itated with galectin antisera, we found that galectin-1 containing spliceosomes did not contain galec

94 sensitivity of GluA4 AMPA receptors to human galectin-1 could be enhanced by supplementation of cultu

95 tion of cell apoptosis, we hypothesized that Galectin-1 could interact with CD146, leading to functio

96 The major galectin-1 counter-receptor on both dendritic cell popul

97 on, with loss of core 2 O-glycan ligands for galectin-1 created by core 2 beta1,6-N-acetylglucosaminy

98 n patients with renal cell carcinoma and the galectin-1-CXCR4 axis may serve as a therapeutic target

99 hocytes in TLR5-responsive tumors to secrete galectin-1, dampening antitumor immunity and acceleratin

100 Loss of CD43 expression reduced galectin-1 death of murine thymocytes and human T lympho

101 ne externalization or DNA degradation during galectin-1 death.

102 ced ERK signaling was sustained in activated galectin-1-deficient CD8 T cells and antagonized by reco

103 We found that galectin-1-deficient CD8 T cells undergo greater cell di

104 In vitro experiments demonstrated that galectin-1-deficient GL26-Cit glioma cells are approxima

105 Conversely, galectin-1-deficient glioma cells could be eradicated by

106 Binding of dimeric galectin-1 (dGal-1) to glycoconjugates on N-formyl-Met-L

107 We report that human galectin-1 (dGal-1), a small dimeric beta-galactoside-bi

108 lls, whereas LNCaP cells that do not express galectin-1 did not kill T cells.

109 Extracellular galectin-1 directly induces death of T cells and thymocy

110 Recombinant galectin-1 enhanced TCR binding to agonist/MHC complexes

111 y, we underscore the biological relevance of galectin-1-enhanced DC migration by showing that intrade

112 ssue of Immunity, Starossom et al. show that Galectin-1 exerts a neuroprotective function through gly

113 ll fusion and damage, depending on timing of galectin-1 exposure.

114 re sensitive to NK-mediated tumor lysis than galectin-1-expressing cells.

115 umor evasion of immune attack; we found that galectin-1-expressing prostate cancer cells killed bound

116 Galectin-1 expression also promoted TCR agonist-driven C

117 In contrast, galectin-1 expression antagonized ERK activity in thymoc

118 unoblots and PCR studies confirmed increased galectin-1 expression by hypoxia in several cancer cell

119 Galectin-1 expression opposed TCR partial agonist-driven

120 B cells lacking OCA-B expression, increased galectin-1 expression, secretion, and cell surface assoc

121 and they reversed the effects of morphine on galectin-1 expression.

122 The binding affinity and specificity of galectin-1 for eight different beta-galactosyl terminal

123 s had no surface galectin-3 but used surface galectin-1 for interaction with Gal-3BP to form large ol

124 Galectin-1 (Gal-1) and galectin-3 (Gal-3) exhibit profou

125 t interactions between the regulatory lectin galectin-1 (Gal-1) and specific target N-glycans link tu

126 Following the identification of Galectin-1 (Gal-1) as a downstream effector of p75(NTR),

127 hort, which revealed that increased lymphoma galectin-1 (Gal-1) expression strongly correlated with r

128 Galectin-1 (Gal-1) has been shown to play a major role i

129 tle is known about the role(s) of endogenous galectin-1 (Gal-1) in arthritis.

130 Here we show that Galectin-1 (Gal-1) induces PS exposure independent of al

131 Galectin-1 (Gal-1) is a beta-galactoside-binding protein

132 Galectin-1 (gal-1) is an endogenous lectin with regulato

133 By binding cell surface glycoconjugates, galectin-1 (gal-1) is involved in cell adhesion and migr

134 At concentrations that abrogated galectin-1 (Gal-1) ligand and E-selectin ligand expressi

135 It was recently described that Galectin-1 (Gal-1) promotes axonal growth after spinal c

136 fabricated for the quantitative detection of Galectin-1 (Gal-1) protein, a biomarker for the onset of

137 Galectin-1 (Gal-1) regulates leukocyte turnover by induc

138 fferent stages of the disease, we found that galectin-1 (Gal-1) was the most abundantly expressed gal

139 Galectin-1 (Gal-1), a beta-galactoside-binding lectin, p

140 Galectin-1 (Gal-1), a beta-galactoside-binding protein,

141 Tumor-derived galectin-1 (Gal-1), a beta-galactoside-binding S-type le

142 Galectin-1 (Gal-1), a carbohydrate-binding protein whose

143 Galectin-1 (Gal-1), a glycan-binding protein with broad

144 Galectin-1 (Gal-1), a member of a family of carbohydrate

145 Galectin-1 (Gal-1), a member of a family of evolutionari

146 Galectin-1 (gal-1), a special lectin with high affinity

147 Galectin-1 (Gal-1), an endogenous glycan-binding protein

148 Galectin-1 (gal-1), an endogenous lectin secreted by a v

149 dy we evaluated the therapeutic potential of galectin-1 (gal-1), an endogenous lectin that in some au

150 We investigated the ability of soluble galectin-1 (gal-1), an endogenous lectin that promotes T

151 Here we show that galectin-1 (Gal-1), an endogenous lectin that recognizes

152 Galectin-1 (Gal-1), an evolutionarily conserved beta-gal

153 Moreover, using galectin-1 (Gal-1), an immunomodulatory carbohydrate-bin

154 In this article, we show that galectin-1 (Gal-1), an immunoregulatory lectin widely ex

155 One of these regulators, galectin-1 (Gal-1), possesses both anti-inflammatory and

156 a binding partner for the endogenous lectin galectin-1 (Gal-1), which is known to ameliorate symptom

157 Galectin-1 (Gal-1)-binding to Gal-1 ligands on immune an

158 lopment, bone marrow stromal cells secreting galectin-1 (GAL1) constitute a specific niche for pre-BI

159 Galectin-1 (Gal1) is a member of a highly conserved fami

160 Galectin-1 (GAL1) is an S-type lectin with multiple func

161 The glycan-binding protein galectin-1 (Gal1) is highly expressed in PDAC stroma, bu

162 l lines (LCLs) and primary PTLDs overexpress galectin-1 (Gal1), a carbohydrate-binding lectin that in

163 These include galectin-1 (gal1), a lectin with apoptotic activity on a

164 Here, we identified Galectin-1 (Gal1), an endogenous glycan-binding protein,

165 Galectin-1 (Gal1), an evolutionarily conserved glycan-bi

166 We previously showed that galectin-1 (GAL1), produced by bone marrow stromal cells

167 the immunoregulatory glycan-binding protein, galectin-1 (Gal1), through an AP1-dependent enhancer.

168 ace glycome selectively regulated binding of galectin-1 (Gal1), which upon recognition of complex N-g

169 core 2 O-glycans (high affinity ligands for galectin-1), galectin-1 signaling in cells expressing a

170 osis similar to that of a known nonselective galectin-1/galectin-3 inhibitor, which strongly suggests

171 In this article, we show that galectin-1 gene and protein expression are potentiated b

172 Knockdown of galectin-1 gene expression in renal cancer cell lines re

173 tor, TGF-beta, hepatocyte growth factor, and galectin-1 gene expression levels varied among donors.

174 merase, pancreatic; tropomyosin 2 (TM2); and galectin-1] had been associated previously with pancreat

175 1 susceptibility and synthesis of endogenous galectin-1 has been proposed to promote tumor evasion of

176 positively regulate T cell susceptibility to galectin-1, identifying a novel function for CD43 in con

177 Vimentin, cystatin C, galectin-1, IGFBP-7, and secreted protein, acidic and ri

178 We found significant overexpression of galectin-1 in both kidney cancer cell lines and metastat

179 ypoxic induction of this secreted protein as galectin-1 in cell lines and xenografts.

180 mphatic endothelial cells, and deposition of galectin-1 in extracellular matrix selectively regulates

181 roviding additional evidence for the role of galectin-1 in immune-endocrine cross-talk.

182 These findings define a novel role for galectin-1 in inhibiting tissue emigration of immunogeni

183 However, the role of galectin-1 in kidney cancer remains elusive.

184 ion by showing that intradermal injection of galectin-1 in MRL-fas mice, which have a defect in skin

185 mergence of hormonal and redox regulation of galectin-1 in placental mammals may be implicated in mat

186 we show conserved placental localization of galectin-1 in primates and its predominant expression in

187 This study evaluated the role of galectin-1 in the progression and clinical prognosis of

188 Silencing galectin-1 increased and adding exogenous galectin-1 sup

189 t CD8 T cells and antagonized by recombinant galectin-1, indicating galectin-1 modulates TCR feed-for

190 eficient cells displayed enhanced binding to galectin-1, indicating that changes in GNE activity can

191 Thus, extracellular galectin-3 and galectin-1 induce death of T cells through distinct cell

192 ted, we propose that increased expression of galectin-1 induced by morphine may modulate HIV-1 infect

193 Additional studies suggested that galectin-1 induced CXCR4 expression through activation o

194 Resistance to galectin-1-induced apoptosis may directly contribute to

195 However, events in galectin-3- and galectin-1-induced cell death differ in a number of ways

196 CD45, or if fodrin degradation is prevented, galectin-1-induced cell death is not accompanied by memb

197 other glycoprotein receptors is critical for galectin-1-induced cross-linking and T cell death, galec

198 Syk and protein kinase C signaling abrogated galectin-1-induced DC activation as monitored by interle

199 lthough roles for CD7 and CD45 in regulating galectin-1-induced death have been described, the requir

200 In addition, CD7 that is required for galectin-1-induced death is not required for death trigg

201 We describe a novel role for CD43 in galectin-1-induced death, and the effects of O-glycan mo

202 We observed a Galectin-1-induced HUVEC apoptosis in a dose-dependent m

203 MDDCs and immediate downstream effectors of galectin-1-induced MDDC activation and migration.

204 ly and promoting phagocytic clearance during galectin-1-induced T cell death.

205 In this study, we show that galectin-1 induces a phenotypic and functional maturatio

206 Therefore, galectin-1, inducibly expressed by activated CD8 T cells

207 The presence of galectin-1 inhibits migration of immunogenic dendritic c

208 -immunoprecipitation experiments showed that Galectin-1 interacts with endogenous CD146 that is highl

209 ain of galectin-3 inhibited incorporation of galectin-1 into splicing complexes, explaining the domin

210 Galectin-1 is a galactoside-binding lectin expressed in

211 Galectin-1 is a lectin produced by vascular cells that c

212 Galectin-1 is a member of a family of beta-galactoside-b

213 Galectin-1 is a member of the conserved beta-galactoside

214 Galectin-1 is a member of the galectin family of glycan-

215 Our findings show that galectin-1 is a novel endogenous activator of human MDDC

216 Galectin-1 is a novel hypoxia-regulated protein and a pr

217 Here, we show that galectin-1 is also highly expressed by human lymphatic e

218 Galectin-1 is an anti-inflammatory lectin with pleiotrop

219 Galectin-1 is an endogenous carbohydrate-binding protein

220 Galectin-1 is an endogenous carbohydrate-binding protein

221 The mammalian lectin galectin-1 is highly expressed by vascular endothelial c

222 Galectin-1 is involved in pathological disorders like tu

223 Galectin-1 is known to play a role in immune regulation

224 is, galectins, we tested the hypothesis that Galectin-1 is relevant for causing degeneration.

225 Finally, galectin-1 is shown to negatively regulate B cell prolif

226 One unique effect of galectin-1 is to increase DC migration through the ECM,

227 f core 1 O-glycans (low affinity ligands for galectin-1) is sufficient to overcome lack of core 2 O-g

228 between the two galectins, as galectin-9 and galectin-1 killed different subsets of murine thymocytes

229 susceptibility to the two galectins: whereas galectin-1 kills double-negative and double-positive hum

230 Galectin-1 kills immature thymocytes and activated perip

231 Galectin-1 knockdown decreased CXCR4 expression levels i

232 Moreover, mice injected with galectin-1 knockdown Lewis lung carcinoma showed decreas

233 Binding to galectin-1 lattice at the extracellular surface leads to

234 Importantly, at the genes encoding galectin-1 (Lgals1), and mothers against decapentaplegic

235 he secreted beta-galactoside binding protein Galectin 1-like 2 (Drgal1-L2).

236 C migration through the ECM, suggesting that galectin-1 may be an important component in initiating a

237 We observed direct evidence for galectin-1-mediated extended cross-linking on the engine

238 was investigated for its ability to inhibit galectin-1-mediated T-cell agglutination.

239 hibitors led to dose-dependent impairment of Galectin-1-mediated transcriptional activation.

240 onized by recombinant galectin-1, indicating galectin-1 modulates TCR feed-forward/feedback loops inv

241 In order to exhibit an enhancing effect, galectin-1 must be present during the initial phase of v

242 gonists of the effect of lung cancer-derived galectin-1 on DCs and anti-HB-EGF blocking antibodies co

243 common death trigger receptors recognized by galectin-1 on different types of cancer cells.

244 to contribute to the differential effect of galectin-1 on migration.

245 f virus attachment; in contrast, addition of galectin-1 postinfection results in reduced production o

246 Treatment of galectin-1, present in large amounts in lung cancer cond

247 Finally, galectin-1 produced by activated Ag-specific CD8 T cells

248 dentify a complex set of mechanisms by which galectin-1 prolongs cell-surface retention of VEGF recep

249 Our findings suggest that galectin-1 promotes tumor progression through upregulati

250 Here, we identify the galectin-1 receptors on MDDCs and immediate downstream e

251 ; however, we have found that galectin-9 and galectin-1 require different glycan ligands and glycopro

252 t for loss of core 2 O-glycan expression and galectin-1 resistance.

253 though MF cells are typically CD7-, and thus galectin-1 resistant, CD7+ HH cells, derived from a pati

254 minyltransferase, which is down-regulated in galectin-1-resistant PSA(-) LNCaP cells compared with ga

255 ositive (PSA(+)) LNCaP cells compared with a galectin-1-resistant PSA(-) LNCaP subclone.

256 e first to indicate that lung cancer-derived galectin-1 secretion is responsible for stimulating tumo

257 1-resistant PSA(-) LNCaP cells compared with galectin-1-sensitive PSA(+) LNCaP cells.

258 d expression of glycosyltransferase genes in galectin-1-sensitive, prostate-specific antigen-positive

259 an ligands that are important for conferring galectin-1 sensitivity in these cells, and analyzed expr

260 To understand the mechanism of galectin-1 sensitivity of LNCaP cells compared with othe

261 nsferase 1 rendered LNCaP cells resistant to galectin-1, showing that specific O-glycans are critical

262 Furthermore, regulation of galectin-1 signaling by alpha2,6-sialylation of N-glycan

263 cans (high affinity ligands for galectin-1), galectin-1 signaling in cells expressing a high molecula

264 While galectin-1 signaling in cells expressing low molecular w

265 Here we show that galectin-1 signaling through CD45, which carries both N-

266 ells, and restoration of CXCR4 expression in galectin-1-silenced cells rescued cell motility and clon

267 lectin galectin-3; galectin-3 siRNA but not galectin-1 siRNA prevented MUC1-induced upregulation of

268 notechnology approach that uses gold nanorod-galectin-1 small interfering RNA complexes (nanoplexes)

269 ity to galectin-3 but maintained affinity to galectin-1 suppressed chemokine expression.

270 ng galectin-1 increased and adding exogenous galectin-1 suppressed chemokine responses to Trichomonas

271 Galectin-1 suppressed chemokines that facilitate recruit

272 Our findings suggest that galectin-1 suppression in human glioma could improve pat

273 Loss of galectin-1 susceptibility and synthesis of endogenous ga

274 is the same glycosyltransferase required for galectin-1 susceptibility of T lymphoma cells, indicatin

275 ing that specific O-glycans are critical for galectin-1 susceptibility.

276 e show that fodrin degradation occurs during galectin-1 T cell death and that CD45 is essential for f

277 Thus, N- and O-glycans modulate galectin-1 T cell death by distinct mechanisms, and diff

278 Regulation of galectin-1 T cell death by O-glycans is mediated through

279 lular death pathways, as galectin-9, but not galectin-1, T cell death was blocked by intracellular Bc

280 Although 0118 is a topomimetic of galectin-1-targeting angiostatic amphipathic peptide Ang

281 ls lacking CD43 bound approximately 50% less galectin-1 than T cells expressing CD43.

282 are resistant to apoptotic agents, including galectin-1 that is abundant in skin.

283 ial cells express the innate immune effector galectin-1 that we have previously shown can bind to spe

284 t the acquired immunoregulatory functions of galectin-1 then became highly conserved in eutherian lin

285 assays show that 0118 attenuates binding of galectin-1 to cell surface glycans, and the inhibition o

286 Binding of galectin-1 to immunogenic dendritic cells reduces phosph

287 increased the preference for galectin-3 over galectin-1 to more than 200-fold.

288 Indeed, compared with LPS, galectin-1-treated human MDDCs exhibited significantly b

289 However, unlike LPS-matured DCs, galectin-1-treated MDDCs did not produce the Th1-polariz

290 Immature human MDDCs exposed to galectin-1 up-regulated cell surface markers characteris

291 unohistochemical analysis substantiated that Galectin-1 upregulation is associated with osteoarthriti

292 ar-dependent binding of recombinant CD146 to Galectin-1 using both ELISA and Biacore assays.

293 A growth inhibitor, galectin-1, was downregulated in the high producer, whic

294 However, galectin-3, but not galectin-1, was expressed in the DCT.

295 of the tandem repeat galectin-9 and dimeric galectin-1, we created a series of bivalent constructs w

296 Plasma levels of galectin-1 were higher in tumor-bearing severe combined

297 2 O-glycan expression and susceptibility to galectin-1, whereas mutant enzyme lacked activity and di

298 We found that galectin-1, which is made by inflamed endothelial cells,

299 In this way, galectin-1 widens the distinction between TCR-directed f

300 ns, and a reported inhibitory interaction of galectin-1 with CD45, the phosphatase activity of CD45 i